Kidney Cancer

FDA grants nivolumab/cabozantinib combo priority review in kidney cancer

October 19, 2020

The FDA is reviewing data from the phase 3 CheckMate-9ER trial, which showed that the combination significantly improved progression-free and overall survival compared with sunitinib in frontline renal cell carcinoma.

FDA issues draft guidance for adjuvant trials in bladder cancer, renal cell carcinoma

October 02, 2020

"Currently, there is significant variability in the design, conduct, and analysis of clinical trials for adjuvant treatment of both kidney cancer and bladder cancer. This variability negatively affects our ability to interpret trial results," said Richard Pazdur, MD.

Tivozanib May Be Superior Treatment for Patients With RCC, Study Finds

May 29, 2020

When compared with sorafenib, tivozanib showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma.

RCC 2018: Systemic therapy landscape sees rapid change

January 18, 2019

Dr. Kutikov discuss several noteworthy studies about kidney cancer from 2018.

RCC 2018: Top advances in treatment of localized, advanced disease

January 18, 2019

"2018 was an exciting and productive year for kidney cancer research," write Amr A. Elbakry, MBBCh, MSc, and Ketan K. Badani, MD.

ISGF3 activation may inhibit tumor growth in clear cell RCC patients

December 03, 2018

Activating interferon stimulated gene factor 3 could be a new direction for treating clear cell renal cell carcinoma, according to a recent study.

Advanced RCC combo Tx significantly improves PFS

December 03, 2018

“The efficacy benefit and the favorable safety profile support aveluamb plus axitinib as a new first-line standard of care for advanced RCC,” says researcher Robert J. Motzer, MD.